JP2013508298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508298A5 JP2013508298A5 JP2012534412A JP2012534412A JP2013508298A5 JP 2013508298 A5 JP2013508298 A5 JP 2013508298A5 JP 2012534412 A JP2012534412 A JP 2012534412A JP 2012534412 A JP2012534412 A JP 2012534412A JP 2013508298 A5 JP2013508298 A5 JP 2013508298A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- group
- heterocyclic ring
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 138
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- 125000002837 carbocyclic group Chemical group 0.000 claims description 87
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 86
- 229910052760 oxygen Inorganic materials 0.000 claims description 81
- 229910052757 nitrogen Inorganic materials 0.000 claims description 80
- 229910052717 sulfur Inorganic materials 0.000 claims description 68
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 66
- 239000001301 oxygen Substances 0.000 claims description 66
- 125000005842 heteroatom Chemical group 0.000 claims description 61
- 239000011593 sulfur Chemical group 0.000 claims description 55
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 51
- 125000003118 aryl group Chemical group 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 150000002148 esters Chemical class 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 49
- 239000000651 prodrug Substances 0.000 claims description 48
- 229940002612 prodrug Drugs 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 46
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 22
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000000813 microbial effect Effects 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 206010062255 Soft tissue infection Diseases 0.000 claims description 6
- 206010040872 skin infection Diseases 0.000 claims description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 4
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010056519 Abdominal infection Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- HCUOEKSZWPGJIM-IYNMRSRQSA-N (e,2z)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N\O)\C(N)=O HCUOEKSZWPGJIM-IYNMRSRQSA-N 0.000 claims description 2
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims description 2
- 206010060968 Arthritis infective Diseases 0.000 claims description 2
- 208000031729 Bacteremia Diseases 0.000 claims description 2
- 206010014889 Enterococcal infections Diseases 0.000 claims description 2
- 206010018612 Gonorrhoea Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010058674 Pelvic Infection Diseases 0.000 claims description 2
- 206010035148 Plague Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010058028 Shunt infection Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 208000001786 gonorrhea Diseases 0.000 claims description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 2
- 229960003907 linezolid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 12
- 150000001721 carbon Chemical class 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010035737 Pneumonia viral Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000009421 viral pneumonia Diseases 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000022338 anthrax infection Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25247809P | 2009-10-16 | 2009-10-16 | |
| US61/252,478 | 2009-10-16 | ||
| US31428710P | 2010-03-16 | 2010-03-16 | |
| US61/314,287 | 2010-03-16 | ||
| US35820110P | 2010-06-24 | 2010-06-24 | |
| US61/358,201 | 2010-06-24 | ||
| PCT/US2010/052924 WO2011047320A2 (en) | 2009-10-16 | 2010-10-15 | Antimicrobial compounds and methods of making and using the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016037911A Division JP2016153405A (ja) | 2009-10-16 | 2016-02-29 | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
| JP2017148530A Division JP2018024653A (ja) | 2009-10-16 | 2017-07-31 | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508298A JP2013508298A (ja) | 2013-03-07 |
| JP2013508298A5 true JP2013508298A5 (enExample) | 2013-11-07 |
| JP6274723B2 JP6274723B2 (ja) | 2018-02-07 |
Family
ID=44343889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534412A Expired - Fee Related JP6274723B2 (ja) | 2009-10-16 | 2010-10-15 | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9023843B2 (enExample) |
| EP (2) | EP3421476A1 (enExample) |
| JP (1) | JP6274723B2 (enExample) |
| KR (1) | KR20180051676A (enExample) |
| CN (1) | CN102712657A (enExample) |
| AU (3) | AU2010306647B9 (enExample) |
| BR (1) | BR112012008759A2 (enExample) |
| CA (1) | CA2777739A1 (enExample) |
| DK (1) | DK2488532T3 (enExample) |
| EA (1) | EA201270568A1 (enExample) |
| ES (1) | ES2683311T3 (enExample) |
| IL (2) | IL219134B (enExample) |
| MX (2) | MX2012004341A (enExample) |
| NZ (1) | NZ599289A (enExample) |
| PH (2) | PH12012500734A1 (enExample) |
| WO (1) | WO2011047320A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9216979B2 (en) | 2009-10-16 | 2015-12-22 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| PH12012500734A1 (en) | 2009-10-16 | 2012-11-26 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| EP3039025A4 (en) | 2013-09-09 | 2017-05-31 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| AU2014315045A1 (en) | 2013-09-09 | 2016-03-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| WO2015064714A1 (ja) * | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| KR20180015114A (ko) | 2015-03-11 | 2018-02-12 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 이의 제조 및 사용 방법 |
| JP2017061430A (ja) * | 2015-09-25 | 2017-03-30 | 芳男 ▲浜▼田 | 新規なプロドラッグ |
| EP3452479A1 (en) * | 2016-05-06 | 2019-03-13 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| WO2025233837A1 (en) | 2024-05-07 | 2025-11-13 | Takeda Pharmaceutical Company Limited | 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624731A (en) | 1953-01-06 | S-phenylpyrimidkn e x derivativesx | ||
| US3980781A (en) | 1966-03-31 | 1976-09-14 | Imperial Chemical Industries Limited | Fungicidal composition and method containing 2-amino-pyrimidines |
| US3673184A (en) * | 1970-09-02 | 1972-06-27 | Dainippon Pharmaceutical Co | Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives |
| JPS5821681B2 (ja) | 1974-12-05 | 1983-05-02 | 株式会社三井三池製作所 | 電磁探傷装置によるワイヤロ−プ位置判別検出装置 |
| US4361557A (en) | 1980-01-28 | 1982-11-30 | Schering Corporation | 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ZA835684B (en) | 1982-08-27 | 1985-03-27 | Roussel Uclaf | Imidazo(1,2-a)pyrimidines |
| US5332835A (en) | 1984-02-03 | 1994-07-26 | Zambon S.P.A. | Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process |
| JPS6191184A (ja) | 1984-10-08 | 1986-05-09 | Morishita Seiyaku Kk | ２−アニリノ−５−（１ｈ−テトラゾ−ル−５−イル）ピリミジン−４（３ｈ）−オン誘導体 |
| DE3446812A1 (de) | 1984-12-21 | 1986-06-26 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| JP2873340B2 (ja) | 1988-04-29 | 1999-03-24 | 武田薬品工業株式会社 | 抗生物質ｔａｎ―１０５７，その製造法および用途 |
| JP2549931B2 (ja) | 1990-01-12 | 1996-10-30 | 株式会社大塚製薬工場 | ピリミドベンズイミダゾール誘導体 |
| JP2991382B2 (ja) * | 1990-07-18 | 1999-12-20 | 大日本製薬株式会社 | 縮合三環式化合物およびその塩 |
| US5208141A (en) | 1990-10-09 | 1993-05-04 | Konica Corporation | Silver halide color photographic light-sensitive material |
| JP2811230B2 (ja) | 1990-10-17 | 1998-10-15 | コニカ株式会社 | 新規な写真用カプラー |
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US6451968B1 (en) | 1991-05-24 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Peptide nucleic acids |
| US5766855A (en) | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
| US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| US5646163A (en) | 1992-10-30 | 1997-07-08 | The Procter & Gamble Company | Quinolone 5-(N-heterosubstituted amino) antimicrobials |
| FR2700086B1 (fr) | 1992-12-30 | 1995-04-28 | Alcatel Radiotelephone | Procédé de transmission d'informations à débit élevé par allocation multiple de blocs, procédé de réception associé et dispositif de réception pour sa mise en Óoeuvre. |
| EP0698013B1 (en) | 1993-05-12 | 2001-10-04 | E.I. Du Pont De Nemours And Company | Fungicidal fused bicyclic pyrimidinones |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5668127A (en) | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
| TW424090B (en) | 1995-08-18 | 2001-03-01 | Nat Science Council | Pyrimidines as folate antimetabolites with selective activity against human brain cancer |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US7282327B2 (en) | 1996-01-23 | 2007-10-16 | Affymetrix, Inc. | Nucleic acid labeling compounds |
| GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
| CA2297055A1 (en) | 1997-08-07 | 1999-02-18 | Research Corporation Technologies, Inc. | Antibiotic for methicillin resistant bacteria |
| ATE284407T1 (de) | 1997-11-07 | 2004-12-15 | Isis Pharmaceuticals Inc | Pyrimidinderivate als markierte bindungspartner |
| US6028183A (en) | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
| DE19838998A1 (de) | 1998-08-27 | 2000-03-09 | Bayer Ag | Neue Naturstoffderivate |
| SE9903894D0 (sv) | 1999-10-28 | 1999-10-28 | New Pharma Research Ab | Novel compounds |
| EP1113008A1 (en) | 1999-12-29 | 2001-07-04 | Pfizer Products Inc. | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents |
| KR100358083B1 (ko) | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
| KR101005299B1 (ko) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| DE10061538A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Ureido-Dihydropyrimidinone |
| DE10061542A1 (de) | 2000-12-11 | 2002-06-13 | Bayer Ag | Alkanoylamino-pyrimidine |
| DE10061537A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | beta-Alanin-Derivate |
| DE10061541A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Arylamino-Dihydropyrimidinone |
| HUP0303410A3 (en) * | 2000-12-14 | 2005-12-28 | Procter & Gamble | Antimicrobial quinolones, pharmaceutical compositions containing them and their use |
| US6900215B2 (en) | 2000-12-15 | 2005-05-31 | Merck Sharp & Dohme Ltd. | Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| JP4542311B2 (ja) * | 2001-01-29 | 2010-09-15 | バイオ−ラッド ラボラトリーズ インコーポレイテッド | 核酸誘導体 |
| TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| US20030207804A1 (en) | 2001-05-25 | 2003-11-06 | Muthiah Manoharan | Modified peptide nucleic acids |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US20030158403A1 (en) | 2001-07-03 | 2003-08-21 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| DE10133277A1 (de) | 2001-07-09 | 2003-01-23 | Bayer Ag | ß-Alanin-Derivate |
| DE10141271A1 (de) | 2001-08-23 | 2003-03-06 | Bayer Ag | Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung |
| JP4306206B2 (ja) | 2001-09-04 | 2009-07-29 | 住友化学株式会社 | イミダゾ［１，２−ａ］ピリミジン、その用途およびその製造中間体 |
| DE10208256A1 (de) | 2002-02-26 | 2003-09-04 | Bayer Ag | Piperidinouracile |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| CN1649829A (zh) | 2002-03-08 | 2005-08-03 | 先灵-普劳有限公司 | 新型氟苯尼考类抗生素 |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
| EP1660500B1 (en) | 2003-07-30 | 2007-12-12 | Laboratorios S.A.L.V.A.T., S.A. | Substituted imidazopyrimidines for the prevention and treatment of cancer |
| WO2005019228A1 (en) | 2003-08-12 | 2005-03-03 | Achillion Pharmaceuticals, Inc. | Isothiazoloquinolones and related compounds as anti-infective agents |
| TW200509938A (en) | 2003-08-26 | 2005-03-16 | Teijin Pharma Ltd | Pyrrolopyrimidine thion derivatives |
| TW200524880A (en) | 2003-10-21 | 2005-08-01 | Sankyo Co | Pyrimidine compounds |
| EP1781788A2 (en) | 2004-06-30 | 2007-05-09 | ZGene A/S | Chicken deoxycytidine and deoxyadenosine kinase enzymes and their use |
| DK1913004T3 (da) * | 2005-07-27 | 2011-01-10 | Achillion Pharmaceuticals Inc | 8-methoxy-9h-isothiazolo[5,4-b]quinolin-3,4-dioner og beslægtede forbindelser som antiinfektive midler |
| CN101360720A (zh) | 2005-11-15 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基嘧啶酮衍生物及其用途 |
| NZ544187A (en) | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP2007270087A (ja) | 2006-03-31 | 2007-10-18 | Fujifilm Corp | 硬化性組成物、インク組成物、インクジェット記録方法、印刷物、平版印刷版の製造方法、及び平版印刷版 |
| DE602007012161D1 (de) | 2006-03-03 | 2011-03-10 | Fujifilm Corp | Härtbare Zusammensetzung, Tintenzusammensetzung, Tintenstrahlaufzeichnungsverfahren und Flachdruckplatte |
| WO2007101871A1 (de) | 2006-03-08 | 2007-09-13 | Basf Se | Substituierte imidazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel |
| AU2007270276A1 (en) | 2006-07-03 | 2008-01-10 | Sk Chemicals Co., Ltd. | Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
| KR20080003599A (ko) | 2006-07-03 | 2008-01-08 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법 |
| US20100112561A1 (en) | 2006-08-25 | 2010-05-06 | Stefan Lutz | Fluorescent nucleoside analogues |
| ES2362805T3 (es) | 2006-09-07 | 2011-07-13 | Industrial Research Limited | Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas. |
| EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| WO2008143730A2 (en) | 2007-02-28 | 2008-11-27 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| CA2680177A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| CA2688432A1 (en) | 2007-05-30 | 2008-12-11 | Schering-Plough Ltd. | A process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol |
| WO2008154642A2 (en) | 2007-06-12 | 2008-12-18 | Achaogen, Inc. | Antibacterial agents |
| US20110046142A1 (en) | 2007-06-13 | 2011-02-24 | Northeastern University | Antibiotic compounds |
| GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
| KR20090098710A (ko) | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
| US20100190747A1 (en) | 2009-01-27 | 2010-07-29 | Hideo Suzuki | Fused ring compound and use thereof |
| WO2011017319A1 (en) | 2009-08-03 | 2011-02-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein polymerization |
| ES2620177T3 (es) | 2009-10-15 | 2017-06-27 | Guerbet | Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas |
| SG10201406634VA (en) | 2009-10-16 | 2014-11-27 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| AU2010306646B2 (en) | 2009-10-16 | 2016-09-01 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| PH12012500734A1 (en) | 2009-10-16 | 2012-11-26 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| US9216979B2 (en) | 2009-10-16 | 2015-12-22 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| CA2829993A1 (en) | 2011-03-15 | 2012-09-20 | Rib-X Pharmaceuticals, Inc. | Antimicrobial agents |
| JP6317669B2 (ja) | 2011-04-15 | 2018-04-25 | メリンタ セラピューティクス インコーポレイテッド | 抗菌化合物ならびにそれを作製および使用する方法 |
| JP5821681B2 (ja) | 2012-02-16 | 2015-11-24 | カシオ電子工業株式会社 | 画像形成装置 |
| EP3039025A4 (en) | 2013-09-09 | 2017-05-31 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| AU2014315045A1 (en) | 2013-09-09 | 2016-03-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| KR20180015114A (ko) | 2015-03-11 | 2018-02-12 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 이의 제조 및 사용 방법 |
-
2010
- 2010-10-15 PH PH1/2012/500734A patent/PH12012500734A1/en unknown
- 2010-10-15 EP EP18166633.0A patent/EP3421476A1/en not_active Withdrawn
- 2010-10-15 NZ NZ599289A patent/NZ599289A/en not_active IP Right Cessation
- 2010-10-15 MX MX2012004341A patent/MX2012004341A/es active IP Right Grant
- 2010-10-15 AU AU2010306647A patent/AU2010306647B9/en not_active Ceased
- 2010-10-15 WO PCT/US2010/052924 patent/WO2011047320A2/en not_active Ceased
- 2010-10-15 DK DK10824204.1T patent/DK2488532T3/en active
- 2010-10-15 EP EP10824204.1A patent/EP2488532B1/en not_active Not-in-force
- 2010-10-15 CN CN2010800573380A patent/CN102712657A/zh active Pending
- 2010-10-15 MX MX2015009863A patent/MX359743B/es unknown
- 2010-10-15 US US13/501,836 patent/US9023843B2/en not_active Expired - Fee Related
- 2010-10-15 EA EA201270568A patent/EA201270568A1/ru unknown
- 2010-10-15 ES ES10824204.1T patent/ES2683311T3/es active Active
- 2010-10-15 JP JP2012534412A patent/JP6274723B2/ja not_active Expired - Fee Related
- 2010-10-15 BR BR112012008759-2A patent/BR112012008759A2/pt not_active IP Right Cessation
- 2010-10-15 CA CA2777739A patent/CA2777739A1/en not_active Abandoned
- 2010-10-15 KR KR1020187013069A patent/KR20180051676A/ko not_active Ceased
-
2012
- 2012-04-15 IL IL219134A patent/IL219134B/en not_active IP Right Cessation
-
2015
- 2015-04-08 US US14/681,806 patent/US9573962B2/en not_active Expired - Fee Related
- 2015-10-13 PH PH12015502375A patent/PH12015502375B1/en unknown
-
2016
- 2016-09-22 AU AU2016231569A patent/AU2016231569A1/en not_active Abandoned
-
2017
- 2017-01-05 US US15/399,159 patent/US10259825B2/en not_active Expired - Fee Related
-
2018
- 2018-03-04 IL IL257837A patent/IL257837A/en unknown
- 2018-03-22 AU AU2018202061A patent/AU2018202061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508297A5 (enExample) | ||
| JP2013508299A5 (enExample) | ||
| JP2013508298A5 (enExample) | ||
| JP2016121171A5 (enExample) | ||
| JP2014510788A5 (enExample) | ||
| US8324264B1 (en) | Inhibitors of bacterial biofilms and related methods | |
| RU2399620C2 (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2007514782A5 (enExample) | ||
| JP2019532928A5 (enExample) | ||
| RU2005100516A (ru) | Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций | |
| JP2007500707A5 (enExample) | ||
| CN108570032A (zh) | 新型罗丹明染料及其在抗致病菌中的应用 | |
| WO2015134171A1 (en) | Heteroarylamide inhibitors of tbk1 | |
| JP2011526286A5 (enExample) | ||
| TWI641372B (zh) | 使用抗生素治療超重和肥胖患者感染的方法 | |
| US9994547B2 (en) | Heteroarylamide inhibitors of TBK1 | |
| US10023602B2 (en) | Hamamelitannin analogues and uses thereof | |
| JP2024009968A5 (enExample) | ||
| TW201904970A (zh) | 抗微生物劑及製造及使用方法 | |
| TW200530255A (en) | 3-pyridiniummethylcefem compound | |
| US20240279247A1 (en) | Prodrugs of boron compounds and their use in treating bacterial infections | |
| CN107400126A (zh) | 新型噁唑烷酮类化合物及其制备方法和在医学上的应用 | |
| JP2017507162A (ja) | 抗菌薬を含む医薬組成物 | |
| WO2014161412A1 (zh) | 一类三环喹诺酮衍生物及其制备方法和用途 | |
| ES2335307T3 (es) | Homomorfolin oxalidinonas como agentes antibacterianos. |